[A22-12] Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2022
Project no.:
A22-12
Commission:
Commission awarded on 01.03.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Patients with X-linked hypophosphataemia (XLH) aged 18 years and older
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G18-05 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G19-15 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| G20-27 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A22-11 | Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-88 | Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |